Learn about the latest financial trends and strategies in our comprehensive article written by a financial expert.

The recent decline in Foghorn Therapeutics' stock was attributed to the discontinuation of another of its products, FHD-286. However, the analysts emphasized that this event does not impact their ...

B. Riley analyst Yuan Zhi reiterates a Buy rating on Mirion (MIR) amid concerns regarding DeepSeek. Over the weekend, reported said China’s ...

B. Riley analyst Kyle Bauser raised the firm’s price target on ClearPoint Neuro (CLPT) to $20 from $15 and keeps a Buy rating ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...

Research analysts at B. Riley increased their FY2024 earnings estimates for FormFactor in a research note issued on Monday, January 27th. B. Riley analyst C. Ellis now forecasts that the semiconductor ...

B. Riley Financial Inc. suspended dividends on a pair of its preferred shares, holding off on cash payments to some investors ...

LOS ANGELES, Jan. 21, 2025 /PRNewswire/ -- B. Riley Financial, Inc. (NASDAQ: RILY) ("B. Riley" or the "Company"), a diversified financial services company, today ...

I have covered B. Riley Financial, Inc. or "B. Riley" (NASDAQ:RILY, NASDAQ:RILYL, NASDAQ:RILYP, NASDAQ:RILYM, NASDAQ:RILYK, NASDAQ:RILYN, NASDAQ:RILYG, NASDAQ:RILYT ...

President Donald Trump plans to sign the Laken Riley Act into law as his administration's first piece of legislation.